Keith W Pratz MD

Director of Leukemia, Hospital of University of Pennsylvania Philadelphia. #Pennmedicine, Alumni Mayo Clinic Rochester (IM’05), Johns Hopkins Hospital (Med Onc)

[Keith W Pratz MD @PratzKW]

Happy to share our report on Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia. Responses enriched in Venetoclax naive patients(70 vs 24% CRc). https://t.co/muvomI9lpj

[Keith W Pratz MD @PratzKW]

@MinoruKanaya @BloodPortfolio Well done paper and important topic to consider the wide variation of venetoclax exposures when considering toxicity. For clinicians, these data reinforce needs for careful attention to meds which may change venetoclax clearance.

[Keith W Pratz MD @PratzKW]

@MarkFaberDO @Papa_Heme @Dr_AmerZeidan I have seen at least two of these in the past few years on the same supplement.

[Keith W Pratz MD @PratzKW]

@LeukDocJZ @beatalleukemia @DrAndyMatthews Our standard of care is to not use prophylactic antifungal agents in newly diagnosed AML when using azacitidine and venetoclax. The original phase I aza/ven protocol excluded azole use and with that early work it became apparent we didn’t see need for routine use.

[Keith W Pratz MD @PratzKW]

Heterogeneity in outcomes specific azole agents was noted with adjusted HR with use of posaconazole of 1.62(p=0.005). Examination of recommended dose adjustments failed to reveal survival differences. Great work by Alex Ambinder(JHU) & @DrAndyMatthews

[Keith W Pratz MD @PratzKW]

Happy to share our work on the impact of antifungal prophylaxis(AFP) on outcomes in newly diagnosed AML treated with venetoclax based therapy. In a real world analysis of 1524 patients, use of AFP was associated with inferior survival(HR 1.19, P=0.004). https://t.co/gyVFI8mjWw

[Keith W Pratz MD @PratzKW]

@PennMDForum @BloodCancerUtd His name is Stefan Barta MD.

[Keith W Pratz MD @PratzKW]

Happy to share the long term outcomes of patients who underwent Allo transplant on the Phase 1b and VIALE- A trials of HMA with Venetoclax. 33 patients with median age of 69 were found to have median survival of 29.9 months post Allo(median fu of 31.6 mo). https://t.co/nCfxd1LmrX

[Keith W Pratz MD @PratzKW]

@BKRagonMD @ASH_hematology Congratulations Brittany and to the whole team. Great to see how the community came together to support this trial.

[Keith W Pratz MD @PratzKW]

Thanks to the organizers for the opportunity to speak. It’s an exciting time to participate in the development of these novel therapies. I believe many people will benefit from these new agents as long as we can get them in the hands of the patients who need them.

[Binaytara @binaytara]

Rapid changes in AML from @PratzKW from @PennMedicine at #HemeSummit25: Novel oral small molecule inhibitors are allowing much larger patient populations access to remission induction. Rapid evolution away from classic regimens. Emerging patient groups who may not need/benefit from transplant. Large need for prospective trials comparing classic vs novel therapies. #AML2025 #ALL #CLLsm #hemepath #lymsm #leusm #MedX #MedTwitter #MedEd

[Keith W Pratz MD @PratzKW]

@AlGarfall @rajshekharucms @BloodCancerTalk The key to this is to make the clinical care overlap with the research as much as feasible. Its incumbent on institutions to support wide research programs to allow those who choose research to be high level contributors to said research.

[Keith W Pratz MD @PratzKW]

Search for novel strategies in TP53 AML reveals mevalonate pathway importance in chemoreststance. Congratulations to @SarahSkuli and team on this work!

[Sarah Skuli @SarahSkuli]

Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for an induction of an adaptive stress response - available online now at Leukemia! Thanks to all co-authors and funding support from @ASH_hematology @ConquerCancerFd @NIH

https://t.co/xpkeXMTVdO

[Keith W Pratz MD @PratzKW]

@DavidSteensma Diagnosis, classification, success and failure are determined by light microscopic definition of more or less than 5% of cells. The clinical heterogeneity of this disease lends itself to overtreatment of less aggressive subtypes and early failures of more aggressive forms.

[Keith W Pratz MD @PratzKW]

@INCMNSZ_Ensena

[Keith W Pratz MD @PratzKW]

Thank you Roberta, for the invitation to review our progress in AML therapy. I also want to thank your colleagues for the thoughtful discussion of complex leukemia cases throughout my visit. I hope we can continue to learn from each other how best to care for our patients!

[Roberta Demichelis @RobertaDemiche3]

Thanks to all the professors and attendees who joined us at this first hematology congress at @incmnszmx @DrWendyStock @garciamanero @PratzKW @AlejandroLazo2 @RubenNiesvizky @GCC_Cortes @EnriqueSoto8 @CarmeloGurnari @Meyaix @patsnavarrete @VazyurVasquez @rajuan_27

[Keith W Pratz MD @PratzKW]

Happy to share my review on Incorporating Molecularly Targeted therapy in frontline therapy for fit patients with AML. With Dr Harry Erba https://t.co/HNZ8TFop7A

[Keith W Pratz MD @PratzKW]

Gracias por invitarme a tu gran conferencia. ¡Fue un honor compartir nuestro trabajo sobre nuevas terapias para LMA!

[Jaime Valdés-Céspedes @JValdesMD]

#tengo90anos Congreso 90 años Instituto Nacional de Cancerología #HematologyTeam @PratzKW @isabelitamia1 #AML #HSCT un gran evento!

[Keith W Pratz MD @PratzKW]

Last day of Leukemia service after an amazing two week rotation with Dr Maleeha Ahmad, Dr Ryan Chow, Dr Eamonn Brace and Dr Lukas Ronner. Humbled by the group coordinated attire and thank the team for their great clinical care and eagerness to learn Leukemia.

[Keith W Pratz MD @PratzKW]

@smbenlazar 50 mg with posaconazole is what we did in Viale-A.

[Keith W Pratz MD @PratzKW]

“The needs of the patient come first” 1910 Dr William J Mayo. Thank all the professionals and institutions who aspire to this, particularly those who sacrifice time away from family this time of year.